Pipeline

Inclusive immuno-oncology therapeutics for broader range of human and veterinary patients.

9Bio is dedicated to advancing immuno-oncology therapeutics, extending the transformative impact of this therapeutic class to a wider spectrum of patients. Our mission encompasses two primary objectives.

Firstly, we strive to address unmet needs in cancer disease indications that, until now, have not benefited from these ground-breaking drugs. These are areas where conventional treatments, primarily surgery and chemotherapy, persist, and five-year survival rates remain constrained.

Secondly, we are committed to expanding the durable use of immuno-oncology therapeutics to patients that are either contraindicated for use or which are commonly required to discontinue use due to complications related to existing comorbidities.

Our dual focus aims to make the powerful benefits immuno-oncology treatments more widely applicable and inclusive across a diverse cancer patient population.

We focus on unlocking the potential of innovative immune modalities, while also leveraging pragmatic value generation of proven therapeutics. Our approach is aimed at advancing health solutions for both human and veterinary patients.

Human Health

Novel modality

Target indication: Stomach and esophageal cancers

9B01x is a protein-based immuno-oncology therapeutic designed for treating cancer indications refractory to existing therapies. 9B01x addresses this unmet need via a pioneering mechanism of action which has to date remained underexplored in cancer therapy.

9B01x development is proceeding with the support and expertise of our partners at University of Laval, University of Montreal, TransBIOTech, and the National Research Council Canada (NRC).

Broadening therapeutic access

Target indication: Multiple solid tumor indications

Target indication: Undisclosed Cancer Indications

9B02x aims to deliver the transformative power of immuno-oncology therapeutics to cancer patients that are presently counter-indicated or otherwise unable to take advantage of existing best-in-class therapies.

9B02x development is proceeding with the support and expertise of private sector partners and our academic and public sector partners at McGill University, Université de Montréal, Université Laval, CERVO, and the National Research Council Canada (NRC).

Reengineering opportunity

Target indication: Undisclosed cancer indications

9B03x is a next generation tumor-targeting antibody drug conjugate (ADC) designed to offer best-in-class safety and tolerability profile to a broad and currently underserved patient population.

Veterinary Medicine

Novel modality

Target indication: Oral melanoma

K9B01x is a protein-based oncology therapeutic for dogs suffering from oral melanoma for which radiation and surgery remain primary therapeutic interventions and offer limited long-term survival prospects.

K9B01x development is proceeding with the support and expertise of our partners at University of Laval, University of Montreal, University of Saskatchewan (Western College of Veterinary Medicine), TransBIOTech, and the National Research Council Canada (NRC).

Checkpoint inhibitor

Target indication: Undisclosed cancer indications

Target indication: Undisclosed Cancer Indications

K9B02x is a checkpoint inhibitor developed for primary use in dogs with mast cell cancers, the most common skin cancer in dogs. Canine mast cell cancers are responsive to surgery if they are treated prior to spreading to lymphatics or other organs. In this case, checkpoint inhibitor therapeutics can contribute to long-term survival and improve quality of life.

K9B02x development is proceeding with the support and expertise of private sector partners and our academic and public sector partners at Université de Montréal, Université Laval, CERVO, and the National Research Council Canada (NRC).